Dulaglutide
FDA approved · RxGLP-1 receptor agonist
Also known as: Trulicity
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 143 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Dulaglutide, sold as Trulicity, is a long-acting prescription GLP-1 receptor agonist made by fusing a modified GLP-1 peptide to part of an antibody, which slows its clearance from the body. It mimics the gut hormone GLP-1, increasing glucose-dependent insulin release, reducing glucagon, and slowing stomach emptying.
What the evidence shows
Dulaglutide is FDA approved for improving blood sugar control in adults and children 10 years and older with type 2 diabetes, and for reducing the risk of major cardiovascular events in adults with type 2 diabetes who have heart disease or cardiovascular risk factors. It is backed by a large human evidence base, with 142 registered trials reaching Phase 4 and over 1,300 published papers, while uses outside its approved indications are not established.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.